EGFR gene mutation is capable of positively regulating the expression of PD-L1 in tumor cells; EGFR-TKI can negatively regulate the expression of PD-L1 by inhibiting the nuclear factor-κB (NF-κB) signaling pathway [96]. The gene discussed is EGFR; the disease is neoplasm.